[Federal Register Volume 62, Number 53 (Wednesday, March 19, 1997)]
[Notices]
[Page 13162]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-6856]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Method of Treating 
Established Colitis Using Antibodies Against IL-12

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
404.7(a)(1)(I), announces that the National Institutes of Health is 
contemplating the grant of a co-exclusive world-wide license to 
Genetics Institute, Inc., a Delaware corporation headquartered in 
Cambridge, Massachusetts, and Protein Design Lab, Inc., a Delaware 
corporation headquartered in Mountain View, California, to practice the 
inventions embodied in U.S. Patent Application 08/547,979 and 
corresponding foreign patent applications entitled ``Method of Treating 
Established Colitis Using Antibodies Against IL-12'' in the field of 
treatment of inflammatory bowel disease. These inventions are owned by 
the Government of the United States of America as represented by the 
Department of Health and Human Services.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.

SUPPLEMENTARY INFORMATION: The patent application discloses a method of 
treating the established criteria colitis of an inflammatory bowel 
disease by administering the antibodies against IL-12. A method for 
evaluating the effectiveness of the IL-12 antibodies in reducing the 
inflammatory response is also presented.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Jaconda Wagner, J.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; Telephone: (301) 496-7735, ext. 284; Facsimile: (301) 402-0220. A 
signed Confidentiality Agreement will be required to receive copies of 
the patent applications. Applications for a license in the field of use 
filed in response to this notice will be treated as objections to the 
grant of the contemplated licenses. Only written comments and/or 
applications for a license which are received by NIH on or before May 
19, 1997, will be considered. Comments and objections submitted to this 
notice will not be made available for public inspection and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 11, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-6856 Filed 3-18-97; 8:45 am]
BILLING CODE 4140-01-M